Iridecentmed invests 500 million baht to penetrate the market of dried cannabis flowers.

Marijuana has not yet reached a dead end. “Iridecentmed” invests 500 million baht to expand the factory, increasing production capacity to 9,000-10,000 kilograms/year, focusing on the market for dried medical flower buds for export. Along with accepting OEM production from upstream to downstream.

Siratcha Patcharasopachai, Chairman of the Executive BoardIridescent Med Company A large producer of integrated medical cannabis in Thailand revealed that in the past several years after cannabis was unlocked, the market has continued to grow.

There is a trend in the use of medical marijuana to promote health, along with consumer knowledge and understanding. in CBD being a substance that has health benefits And it is not psychoactive and is not a drug, causing the market to grow 10 times over the past 3 years. Cannabis itself is still able to develop a variety of products for consumers. There are many business opportunities.

by the products and services of Iridescent Med is divided into 3 groups:

1. Medical cannabis inflorescences Focusing on legal export markets.

2. CBD cosmetic products Such as skin care products, cosmeceuticals, massage oils, pain relief gels

3. CBD dietary supplement products such as jelly for health CBD oil sublingual drops

In this regard, Iridezcentmed There is a plan to invest in building a factory that focuses on the market for high quality medical dried flower buds for export. The investment budget is 500 million baht. The new factory has a production capacity of 9,000-10,000 kilograms/year. There are plans to build a factory in Chonburi province. that uses clean energy left over from power plants of subsidiaries, causing costs and carbon emissions Very low footprint Makes it possible to compete in the world market

By 2026, the company aims to be Asia's number one fully integrated cannabis export producer. By emphasizing consistent high production. and the value of high quality cannabis plants that pass the highest pharmaceutical standards at a cost and competitive production volume including awareness of environmental protection and reducing carbon dioxide emissions by using clean energy to produce food and medicine.